
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BAMBI CRISPR Activation Plasmid (h) | sc-403701-ACT | 20 µg | $397.00 |
BAMBI (BMP and activin membrane-bound inhibitor) encodes a transmembrane pseudoreceptor that resembles type I TGF-β family receptors but lacks the intracellular kinase domain, thereby acting as a context-dependent modulator of BMP and TGF-β/Activin signaling. By influencing SMAD phosphorylation dynamics and receptor complex formation, BAMBI can tune downstream transcriptional programs that govern epithelial–mesenchymal plasticity, differentiation, and inflammatory responses. Dysregulated BAMBI expression has been linked to altered TGF-β pathway output in fibrosis- and inflammation-associated settings and is frequently investigated in tumor microenvironment and metastatic signaling studies. As a regulatory node at the membrane, BAMBI is relevant for dissecting cross-talk between BMP, Wnt/β-catenin, and NF-κB-associated programs in human cell models.
BAMBI CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous BAMBI expression without altering the underlying DNA sequence.
BAMBI CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the BAMBI locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the BAMBI transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous BAMBI expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native BAMBI locus and enabling the study of BAMBI-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of BAMBI pathway restoration in tumor cells with silenced or reduced BAMBI expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.